TriSalus Life Sciences, Inc. (NASDAQ: TLSI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $11.00 price target on the stock.
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping [Yahoo! Finance]
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”